1)日本呼吸器学会COPDガイドライン第6版作成委員会:COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第6版2022.メディカルビュー社,2022
2)Hira D, et al:Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One 13:e0193082, 2018 PMID 29462195
3)Mahler DA, et al:TRONARTO;A randomized, placebo-controlled study of tiotropium/olodaterol delivered via soft mist inhaler in COPD patients stratified by peak inspiratory flow. Int J Chron Obstruct Pulmon Dis 16:2455-2465, 2021 PMID 34511891
4)大道光秀,他:COPD患者における吸気流速調査について.日呼吸会誌49:479-487, 2011
5)白木 昌,他:一秒量低値症例における吸気流速によるドライパウダー製剤間の比較検討.日呼ケアリハ学誌25:244-247, 2015.
6)Vogelmeier C, et al:Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093-1103, 2011 PMID 21428765
7)Decramer ML, et al:Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease(INVIGORATE);A randomised, blinded, parallel-group study. Lancet Respir Med 1:524-533, 2013 PMID 24461613
8)Singh D, et al:Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD(ACLIFORM-COPD);A multicentre, randomised study. BMC Pulm Med 14:178, 2014 PMID 25404569
9)Buhl R, et al:Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD(GOLD 2-4). Eur Respir J 45:969-979, 2015 PMID 25573406
10)Cazzola M, et al:The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23:257-267, 2010 PMID 20381630
11)Buhl R, et al:Efficacy of tiotropium/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are naïve to LAMA, LABA and ICS;Pooled analysis of four clinical trials. Adv Ther 37:4175-4189, 2020 PMID 32671684
12)Muro S, et al:Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients;A pooled analysis. Respirology 25:393-400, 2020 PMID 31339215
13)Martinez FJ, et al:Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest 152:1169-1178, 2017 PMID 28720336
14)Mahler DA, et al:Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD;The BLAZE study. Eur Respir J 43:1599-1609, 2014 PMID 24176997
15)Lipson DA, et al:Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378:1671-1680, 2018 PMID 29668352
16)Papi A, et al:Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease(TRIBUTE);A double-blind, parallel group, randomised controlled trial. Lancet 391:1076-1084, 2018 PMID 29429593
17)Rabe KF, et al:Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383:35-48, 2020 PMID 32579807
18)ZuWallack RL, et al:Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 19:1661-1670, 2001 PMID 11399688
19)Calverley PM, et al:Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int J Chron Obstruct Pulmon Dis 14:2733-2744, 2019 PMID 31819405
20)Pela R, et al:N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66:495-500, 1999 PMID 10575333
21)Ni W, et al:Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation;A meta-analysis. PLoS One 10:e0121257, 2015 PMID 25812085
22)Cao Y, et al:Effects of long-term macrolide therapy at low doses in stable COPD. Int J Chron Obstruct Pulmon Dis:14:1289-1298, 2019 PMID 31354258
23)一ノ瀬正和,他:日本における慢性閉塞性肺疾患(COPD)患者の大規模電話実態調査—Confronting COPD Japan Survey—.日呼吸会誌45:927-935, 2007